Biosimilar Antitrust Pressure On J&J Grows As Walgreen, Kroger Sue Over Remicade Contracts
Executive Summary
Pharmacy chains object to J&J agreements with insurers that block coverage of Pfizer and Merck biosimilars except in 'rarest of circumstances'; seek overcharge damages for Remicade purchases.
You may also be interested in...
Pointing Fingers On Biosimilars: FDA Versus FTC
US FDA is talking tough on antitrust enforcement. But is there any reason to think FTC is listening?
Pointing Fingers On Biosimilars: FDA Versus FTC
US FDA is talking tough on antitrust enforcement. But is there any reason to think FTC is listening?
Biosimilar Substitution: US State Laws Require Physician Communication And, In Some Cases, Lower Prices
Bills allowing pharmacies to substitute biosimilars for reference biologics have been enacted in all but six states. Interactive map notes state-by-state provisions.